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Abstract Bovine iris sphincter in vitro responded to L-
adrenergic stimulation with pronounced relaxation (EC50 of
isoproterenol = 0.3 nM), which was potentiated by the cAMP
phosphodiesterase inhibitor, isobutylmethylxanthine, and mi-
micked by the adenylyl cyclase activator, forskolin. The L1/L2
antagonist, propranolol, exhibited low potency with calculated Ki
of 200 nM. The L3-selective antagonist, bupranolol, exhibited a
biphasic inhibition profile, with calculated Kis of approximately
20^50 and 200^300 nM. The L3-selective agonist, BRL 37344,
elicited 70% of maximal relaxation (EC50 = 30 nM). When
relaxation was induced by BRL 37344, bupranolol exhibited
much higher potency (calculated Ki = 1 nM). Our data suggest
that the L-adrenergic relaxation response in bovine iris sphincter
is mediated by a mixed population of L-adrenergic receptors,
with a predominant contribution of atypical, most likely L3
subtype, receptors.
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1. Introduction
Atypical L-adrenergic receptors have been described quite
often in the pharmacological literature. Recently, some of the
phenomenology ascribed to atypical L-adrenergic responses
has been identi¢ed with a novel receptor subtype, L3-adreno-
ceptor. First found in brown fat (see [1] for review), it has
been subsequently cloned [2^5] and characterized pharmaco-
logically [3,6]. Currently, L3-adrenoceptors have been identi-
¢ed in human brown fat cells [7], colon and gall bladder [8]. A
mutation of the L3-adrenoceptor in Pima Indians, Europeans
and Japanese has been linked to their genetic propensity for
obesity and high incidence of diabetes [9].
We investigated the pharmacology of L-adrenergically
evoked relaxation of bovine iris sphincter. It is generally ac-
cepted that L-adrenergic e¡ects are mediated by an increase in
cellular cAMP. However, in view of the atypical L-adrenergic
characteristics of the bovine sphincter response (see Section 3)
and considering the reports that some of the L-adrenergic
e¡ects may be mediated by NO (e.g. [10^12]), we investigated
the role of cAMP in the L-adrenergic relaxation of the bovine
iris sphincter. Our results conform with the hypothesis that
the relaxation induced by L-adrenergic is most probably medi-
ated to a signi¢cant extent by the L3-adrenoceptor subtype
and proceeds via an increase in cellular cAMP concentrations.
This ¢nding extends the distribution of L3-adrenoceptors to
the ocular smooth muscle.
2. Materials and methods
Bovine eyes were freshly enucleated after the slaughter of the ani-
mal and kept on ice. Eyes were used within 72 h after enucleation.
After removal of the cornea, the iris sphincter was excised. The muscle
was tied at opposing sides and mounted on an isometric tension
apparatus in an organ bath (10 ml) in Krebs-bicarbonate solution.
The assays were conducted essentially as described by Patil [13].
Brie£y, the tension was adjusted to 1 g and the muscle was allowed
to initially relax, then to spontaneously regain its tonus (usually to
more than 1 g tension) over 1^3 h. The bath was continuously aerated
with an O2 :CO2 mixture (95:5%) and kept at a constant temperature
of 32‡C. Drugs were added directly to the bath in a 20^100 Wl volume.
To control for the possible occlusion of the L-blockers by the mel-
anin-rich iris sphincter, we performed a bio-assay of propranolol
(PPL) pre-exposed for 30 min to excised sphincter and then tested
on rat right atria for its inhibition of the positive chronotropic e¡ect
of isoproterenol (ISO). Brie£y, spontaneously contracting right atria
were mounted on the isometric tension apparatus and a dose-response
to ISO was performed. In the absence of PPL, the half-maximal
stimulation of atrial contraction rate was observed at [ISO] = 0.6
nM. 10 nM PPL shifted the EC50 to 0.9 nM and the same value
was obtained with PPL pre-incubated with the bovine sphincter tissue.
Addition of 1 WM PPL shifted the EC50 to 0.4 WM, and for PPL pre-
incubated with a bovine sphincter to 0.1 WM. Hence, although mela-
nin could potentially bind L-adrenergic antagonists, this was found to
be practically negligible. Similar conclusions were reached also by
Patil and Weber [14].
The composition of the Krebs-bicarbonate solution was (in mM):
NaCl 118; KCl 4.7; MgCl2 1.2; CaCl2 2.5; NaHCO3 25; KH2PO4
1.2; glucose 11; pH 7.4. ISO, isobutylmethylxanthine (IBMX), salbu-
tamol (SAL), PPL and forskolin were purchased from Sigma (Israel).
BRL 37344 was purchased from Research Biochemicals, Natick, MA,
USA. Bupranolol was a gift of Schwarz Pharma, Monheim, Germany.
SR 59230A was a gift of Dr. Manara of Sano¢ Midy Research Cen-
ter, Milan, Italy. All other chemicals were of analytical grade.
Grass isometric force transducer type FTO3C and Grass Polygraph
ampli¢er and recorder were used. All experiments were performed
several times on sphincters obtained from di¡erent animals. Results
are presented as means þ S.E.M. Student’s t-test was used to assess the
signi¢cance of the results at P6 0.05.
3. Results
3.1. The e¡ect of L-adrenergic stimulation on basal tension is
mediated by cAMP accumulation
L-Adrenergic stimulation alone caused a signi¢cant relaxa-
tion of basal tension in iris sphincter muscle, mechanically
adjusted to 1 g tension. Addition of 10 nM SAL or 1 nM
ISO (not shown) caused a rapid decrease in basal tension by
0.87 þ 0.21 g (Fig. 1A, n = 10, P6 0.001).
To con¢rm that the L-adrenergic e¡ect was indeed mediated
by an increase in cAMP, we employed forskolin, a diterpene
that stimulates adenylyl cyclase. 10 WM forskolin alone also
caused a major decrease in basal tension (by 0.65 þ 0.15 g,
Fig. 1B, n = 9, P6 0.001). Subsequent addition of 10 nM
SAL did not further decrease basal tension (Fig. 1B). Con-
versely, the addition of forskolin after SAL also did not pro-
duce further relaxation (Fig. 1A). Hence, elevation of cAMP
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alone was su⁄cient to produce maximal relaxation, be it via
stimulation of the L-adrenergic receptors or by direct stimu-
lation of adenylyl cyclase.
In nine out of the 15 experiments performed, the cAMP
phosphodiesterase inhibitor, IBMX (3 WM), potentiated the
relaxing e¡ect of 1 nM ISO (not shown). In six experiments,
there was no e¡ect of IBMX, suggesting that in these experi-
ments ISO alone caused su⁄cient elevation of cAMP to pro-
duce maximal relaxation. Hence, the L-adrenergic relaxation
of bovine iris sphincter appeared to be mediated by cAMP.
3.2. Pharmacological characterization of the response to
L-adrenergic drugs
In order to characterize further the L-agonist-induced relax-
ation of the sphincter, we performed cumulative dose-re-
sponse experiments to L-adrenergic stimulation, either alone
or in the presence of antagonists.
ISO alone caused a dose-dependent relaxation of resting
sphincter, with a half-maximal relaxation (EC50) obtained at
approximately 0.3 nM and maximal e¡ect at 10^30 nM (Fig.
2). The potent L1;2-adrenergic antagonist, PPL, caused com-
petitive inhibition of the ISO-induced relaxation. The appar-
ent EC50 for ISO shifted to 10^20 nM at 10 WM PPL, yield-
ing an approximate Ki value of 0.2 WM. The dose response to
ISO in the presence of PPL spread to over three orders of
magnitude of the concentration of the agonist, suggesting
more than a single receptor population. The low potency of
PPL was not due to its binding to the iris pigment, as deter-
mined by bio-assay on the positive chronotropic e¡ect of ISO
in rat right atria (see Section 2). The very low potency of PPL
and the shape of the dose-response curve (see above) sug-
gested an atypical L-adrenergic response. We therefore tested
the relatively selective L3-adrenoceptor antagonist, buprano-
lol. Bupranolol competitively inhibited ISO-induced relaxa-
tion, with apparent potency equal to or better than PPL.
The apparent EC50 was shifted to 3 and 10 nM at 1 and 10
WM bupranolol, respectively (Fig. 3). This indicated that the
apparent Ki for bupranolol was approximately 0.2 WM. How-
ever, the dose responses to ISO in the presence of bupranolol
were distinctly biphasic, suggesting more than a single popu-
lation of L-adrenoceptors and yielding two di¡erent Ki values
for the antagonist (see Section 4).
1 WM SR 59230A, a putative L3-selective antagonist [15],
had no e¡ect on the response to 10 nM ISO (not shown). It is
known, however, that this compound is fat-soluble and pig-
ment-bound (Dr. Manara, personal communication). It is
possible, therefore, that this lack of e⁄cacy was related to
its sequestration in the pigmented tissue.
To further verify the participation of L3-adrenoceptors in
the relaxation response, we used a selective L3-agonist, BRL
37344 [6]. BRL 37344 alone caused a dose-dependent relaxa-
tion of the iris sphincter with EC50 of 30 nM (Fig. 4). The
maximal e¡ect of BRL 37344 was less than that of ISO (ap-
proximately 70% of maximal L-adrenergic relaxation). The
e¡ect of BRL 37344 was antagonized by 0.1 WM bupranolol.
The apparent EC50 shifted to 3 WM (Fig. 4), yielding a Ki of
approximately 1 nM. BRL 37344 did not, however, fully over-
come the e¡ect of 0.1 WM or 3 nM bupranolol, even at an
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Fig. 1. Non-additivity of SAL and forskolin. Isolated iris sphincter
was pre-equilibrated in the tissue bath, as described in Section 2. 10
nM SAL was added (A, ¢rst downward arrow). When the relaxa-
tion caused by SAL reached a plateau, the tension was re-adjusted
and 10 WM forskolin (FSK) was added (A, second downward ar-
row). An identical experiment, but with the drugs added in the re-
verse order, is shown in B. Tracings from two representative experi-
ments are shown.
Fig. 2. Dose response to ISO. Isolated iris sphincters were mounted
on an isometric tension apparatus and a cumulative dose response
to ISO was performed in the presence of ISO alone (open circles)
or in the presence of 10 WM PLL (closed circles, n = 5). The data
are presented as mean þ S.E.M. % of maximal relaxation (response
to 1 WM ISO, 0.85 þ 0.05 g, n = 19).
Fig. 3. Dose response to ISO in the presence of bupranolol. Isolated
iris sphincters were mounted on an isometric tension apparatus and
a cumulative dose response to ISO was performed in the presence
of ISO alone (open circles), and in the presence of 1.0 (solid
squares, n = 5) or 10 WM (open squares) bupranolol (BUP, n = 8).
The data are presented as mean þ S.E.M. % of maximal relaxation
(response to 1 WM ISO, 0.85 þ 0.05 g, n = 19).
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agonist concentration as high as 30 WM (Fig. 4), suggesting a
non-competitive component in the action of the antagonist.
4. Discussion
L3-Adrenergic receptor pharmacology has been investigated
either in the tissues of origin (mostly fat cells from various
species) or in CHO cells transfected with the receptor cDNA.
In pure systems (i.e. transfectants), the potency of ISO (EC50)
was reported to be in a range of 4^700 nM [3,6]. The L3-
speci¢c agonist, BRL 37344, yielded potency values of 0.4^
80 nM. Hence, our values of 0.3 nM for ISO and 30 nM for
BRL appear to be either more potent or within the same
range. The very wide variations in the reported potencies sug-
gest that the order of potency may be more indicative of
receptor subtypes. However, this parameter also appears to
vary considerably. BRL was reported to be 10-fold more po-
tent than ISO in CHO cells transfected with the mouse recep-
tors, but only 25% as potent in cells transfected with the
human receptor [6]. Similarly, the potencies of PPL and bu-
pranolol vary. In CHO cells transfected with human and
mouse receptors, the Ki of bupranolol was 20 and 12 nM,
respectively [6]. Our results yield Ki values of approximately
0.2 WM, comparable to the L1;2-speci¢c antagonist, proprano-
lol.
Taken together, our results suggest a mixed receptor pop-
ulation with a predominant contribution of L3-adrenoceptors.
The main evidence for this hypothesis is: (1) the clearly bi-
phasic dose response to ISO in the presence of bupranolol,
yielding calculated approximate Ki values of 25^50 and 200^
300 nM; (2) the ability of BRL 37344 to evoke only a partial
response when compared to ISO. This was 70% of maximal
relaxation, which matched the approximate proportion of the
response highly sensitive to bupranolol (approximately 60^
70%); (3) the very high potency of bupranolol to inhibit the
response evoked by BRL 37344. Thus, when the response is
evoked by a speci¢c L3-agonist, it is potently inhibited by a
selective L3-antagonist.
Our results resemble those described for a mixed receptor
population rather than for cells expressing only the L3-adre-
noceptor. Galitzky et al. described a mixed population of L-
adrenoceptors in dog fat cells [16]. Although ISO and BRL
37344 were equie⁄cacious when analyzed for their ability to
induce lipolysis, BRL was only a 60% partial agonist for stim-
ulation of adenylyl cyclase. Similarly, bupranolol was more
potent than PPL in antagonizing the lipolytic e¡ect stimulated
by BRL 37344. Langin et al. [17] demonstrated that buprano-
lol exhibited more than 10-fold potency of PPL in inhibition
of lipolysis induced by BRL 37344 in rat and hamster fat cells.
They have suggested that mammalian fat cells express a mixed
L-adrenoceptor population.
In conclusion, the L-adrenergic relaxation of the bovine iris
sphincter appears to be mediated by a mixed adrenoceptor
population, of which 60^70% may be attributed to atypical,
most probably L3-adrenoceptors.
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Fig. 4. Dose response to BRL 37344 þ bupranolol. Isolated iris
sphincters were mounted on an isometric tension apparatus and a
cumulative dose response to BRL 37344 was performed in the pres-
ence of the agonist alone (solid squares), or in the presence of
0.1 WM bupranolol (BUP, open squares, n = 7). The data are pre-
sented as mean þ S.E.M. % of maximal relaxation (response to 1 WM
ISO, 0.85 þ 0.05 g, n = 19).
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